Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.

IF 8.5 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Diabetology Pub Date : 2024-08-23 DOI:10.1186/s12933-024-02392-y

Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi D Polisetty, Anjali Avinash Patil, Daniyal Ameen, Rakshita Bonu, Samatha P Shetty, Pubali Biswas, Micheal T Ulrich, Negin Letafatkar, Arman Habibi, Mohammad-Hossein Keivanlou, Sara Nobakht, Abdulhadi Alotaibi, Soheil Hassanipour, Ehsan Amini-Salehi

{"title":"Diagnostic and prognostic value of triglyceride glucose index: a comprehensive evaluation of meta-analysis.","authors":"Sandeep Samethadka Nayak, Dona Kuriyakose, Lakshmi D Polisetty, Anjali Avinash Patil, Daniyal Ameen, Rakshita Bonu, Samatha P Shetty, Pubali Biswas, Micheal T Ulrich, Negin Letafatkar, Arman Habibi, Mohammad-Hossein Keivanlou, Sara Nobakht, Abdulhadi Alotaibi, Soheil Hassanipour, Ehsan Amini-Salehi","doi":"10.1186/s12933-024-02392-y","DOIUrl":null,"url":null,"abstract":"Objective: The present umbrella review aims to collate and summarize the findings from previous meta-analyses on the Triglyceride and Glucose (TyG) Index, providing insights to clinicians, researchers, and policymakers regarding the usefulness of this biomarker in various clinical settings.Methods: A comprehensive search was conducted in PubMed, Scopus, and Web of Science up to April 14, 2024, without language restrictions. The AMSTAR2 checklist assessed the methodological quality of the included meta-analyses. Statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software.Results: A total of 32 studies were finally included. The results revealed significant associations between the TyG index and various health outcomes. For kidney outcomes, a high TyG index was significantly associated with an increased risk of contrast-induced nephropathy (CIN) (OR = 2.24, 95% CI: 1.82-2.77) and chronic kidney disease (CKD) (RR = 1.46, 95% CI: 1.32-1.63). High TyG index was significantly associated with an increased risk of type 2 diabetes mellitus (T2DM) (RR = 3.53, 95% CI: 2.74-4.54), gestational diabetes mellitus (GDM) (OR = 2.41, 95% CI: 1.48-3.91), and diabetic retinopathy (DR) (OR = 2.34, 95% CI: 1.31-4.19). Regarding metabolic diseases, the TyG index was significantly higher in patients with obstructive sleep apnea (OSA) (SMD = 0.86, 95% CI: 0.57-1.15), metabolic syndrome (MD = 0.83, 95% CI: 0.74-0.93), and non-alcoholic fatty liver disease (NAFLD) (OR = 2.36, 95% CI: 1.88-2.97) compared to those without these conditions. In cerebrovascular diseases, a higher TyG index was significantly associated with an increased risk of dementia (OR = 1.14, 95% CI: 1.12-1.16), cognitive impairment (OR = 2.31, 95% CI: 1.38-3.86), and ischemic stroke (OR = 1.37, 95% CI: 1.22-1.54). For cardiovascular outcomes, the TyG index showed significant associations with an increased risk of heart failure (HF) (HR = 1.21, 95% CI: 1.12-1.30), atrial fibrillation (AF) (SMD = 1.22, 95% CI: 0.57-1.87), and hypertension (HTN) (RR = 1.52, 95% CI: 1.25-1.85).Conclusion: The TyG index is a promising biomarker for screening and predicting various medical conditions, particularly those related to insulin resistance and metabolic disorders. However, the heterogeneity and methodological quality of the included studies suggest the need for further high-quality research to confirm these findings and refine the clinical utility of the TyG index.","PeriodicalId":9374,"journal":{"name":"Cardiovascular Diabetology","volume":null,"pages":null},"PeriodicalIF":8.5000,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11344391/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Diabetology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12933-024-02392-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The present umbrella review aims to collate and summarize the findings from previous meta-analyses on the Triglyceride and Glucose (TyG) Index, providing insights to clinicians, researchers, and policymakers regarding the usefulness of this biomarker in various clinical settings.

Methods: A comprehensive search was conducted in PubMed, Scopus, and Web of Science up to April 14, 2024, without language restrictions. The AMSTAR2 checklist assessed the methodological quality of the included meta-analyses. Statistical analyses were performed using Comprehensive Meta-Analysis (CMA) software.

Results: A total of 32 studies were finally included. The results revealed significant associations between the TyG index and various health outcomes. For kidney outcomes, a high TyG index was significantly associated with an increased risk of contrast-induced nephropathy (CIN) (OR = 2.24, 95% CI: 1.82-2.77) and chronic kidney disease (CKD) (RR = 1.46, 95% CI: 1.32-1.63). High TyG index was significantly associated with an increased risk of type 2 diabetes mellitus (T2DM) (RR = 3.53, 95% CI: 2.74-4.54), gestational diabetes mellitus (GDM) (OR = 2.41, 95% CI: 1.48-3.91), and diabetic retinopathy (DR) (OR = 2.34, 95% CI: 1.31-4.19). Regarding metabolic diseases, the TyG index was significantly higher in patients with obstructive sleep apnea (OSA) (SMD = 0.86, 95% CI: 0.57-1.15), metabolic syndrome (MD = 0.83, 95% CI: 0.74-0.93), and non-alcoholic fatty liver disease (NAFLD) (OR = 2.36, 95% CI: 1.88-2.97) compared to those without these conditions. In cerebrovascular diseases, a higher TyG index was significantly associated with an increased risk of dementia (OR = 1.14, 95% CI: 1.12-1.16), cognitive impairment (OR = 2.31, 95% CI: 1.38-3.86), and ischemic stroke (OR = 1.37, 95% CI: 1.22-1.54). For cardiovascular outcomes, the TyG index showed significant associations with an increased risk of heart failure (HF) (HR = 1.21, 95% CI: 1.12-1.30), atrial fibrillation (AF) (SMD = 1.22, 95% CI: 0.57-1.87), and hypertension (HTN) (RR = 1.52, 95% CI: 1.25-1.85).

Conclusion: The TyG index is a promising biomarker for screening and predicting various medical conditions, particularly those related to insulin resistance and metabolic disorders. However, the heterogeneity and methodological quality of the included studies suggest the need for further high-quality research to confirm these findings and refine the clinical utility of the TyG index.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

甘油三酯葡萄糖指数的诊断和预后价值：荟萃分析的综合评估。

目的本综述旨在整理和总结以往有关甘油三酯和葡萄糖（TyG）指数的荟萃分析结果，为临床医生、研究人员和政策制定者提供有关该生物标志物在各种临床环境中有用性的见解：截至 2024 年 4 月 14 日，在 PubMed、Scopus 和 Web of Science 上进行了全面检索，无语言限制。AMSTAR2检查表评估了纳入的荟萃分析的方法学质量。统计分析使用综合荟萃分析（CMA）软件进行：最终共纳入 32 项研究。结果显示，TyG指数与各种健康结果之间存在明显关联。在肾脏预后方面，TyG指数高与造影剂诱发肾病（CIN）（OR = 2.24，95% CI：1.82-2.77）和慢性肾病（CKD）（RR = 1.46，95% CI：1.32-1.63）风险增加显著相关。TyG指数高与2型糖尿病（T2DM）（RR = 3.53，95% CI：2.74-4.54）、妊娠糖尿病（GDM）（OR = 2.41，95% CI：1.48-3.91）和糖尿病视网膜病变（DR）（OR = 2.34，95% CI：1.31-4.19）的风险增加明显相关。在代谢性疾病方面，患有阻塞性睡眠呼吸暂停（OSA）（SMD = 0.86，95% CI：0.57-1.15）、代谢综合征（MD = 0.83，95% CI：0.74-0.93）和非酒精性脂肪肝（NAFLD）（OR = 2.36，95% CI：1.88-2.97）的患者的TyG指数明显高于未患有这些疾病的患者。在脑血管疾病方面，TyG指数越高，患痴呆症（OR = 1.14，95% CI：1.12-1.16）、认知障碍（OR = 2.31，95% CI：1.38-3.86）和缺血性中风（OR = 1.37，95% CI：1.22-1.54）的风险越高。在心血管结果方面，TyG指数与心力衰竭（HF）（HR = 1.21，95% CI：1.12-1.30）、心房颤动（AF）（SMD = 1.22，95% CI：0.57-1.87）和高血压（HTN）（RR = 1.52，95% CI：1.25-1.85）风险增加有显著关联：TyG指数是一种很有前景的生物标志物，可用于筛查和预测各种疾病，尤其是与胰岛素抵抗和代谢紊乱有关的疾病。然而，所纳入研究的异质性和方法学质量表明，需要进一步开展高质量的研究，以证实这些发现并完善 TyG 指数的临床实用性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cardiovascular Diabetology 医学-内分泌学与代谢

CiteScore

12.30

自引率

15.10%

发文量

240

审稿时长

1 months

期刊介绍： Cardiovascular Diabetology is a journal that welcomes manuscripts exploring various aspects of the relationship between diabetes, cardiovascular health, and the metabolic syndrome. We invite submissions related to clinical studies, genetic investigations, experimental research, pharmacological studies, epidemiological analyses, and molecular biology research in this field.